Aldosterone-renin screening sales will grow through 2036, led by immunoassay-based kits at 64% of the reagent kits segment in 2026. The market was valued at USD 574.80 million in 2025 and is expected to be worth USD 1185.22 million by 2036, creating an incremental opportunity of USD 571.33 million.